

# CLEAR SYNERGY (OASIS 9)

*CoLchicine and spironolactonE in patients with ST elevation myocARdial infarction who have undergone PCI and SYNERGY Stent Registry – Organization to Assess Strategies of Ischemic Syndromes 9*




Population Health  
Research Institute  
HEALTH THROUGH KNOWLEDGE



Hamilton  
Health  
Sciences





### Primary Endpoints

- 1. Colchicine vs. placebo:** Time to event of the composite of CV death, recurrent MI, or stroke over duration of follow-up
- 2. Spironolactone vs. placebo:** Time to event of the composite of CV death or new or worsening heart failure over duration of follow-up
- 3. SYNERGY Stent Registry\*:** Major adverse cardiac events (MACE) (defined as the composite of CV death, recurrent MI, or unplanned ischemia driven target vessel revascularization) for SYNERGY stent compared to a historical performance goal within 1 year